Wise Pharmacy Recalls Papaverine, Phentolamine, and Alprostadil Injectable Vials
Wise Pharmacy is recalling specific lots of compounded Papaverine/Phentolamine/Alprostadil injectable vials due to a lack of processing controls.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of the product may cause temporary or medically reversible adverse health consequences. The source text does not report any specific injuries or illnesses, aligning with a moderate severity rating for a lack of processing controls.
Plain-English summary
Wise Pharmacy, located in Littleton, Colorado, is recalling 44 vials of Papaverine/Phentolamine/Alprostadil - 30 mg/1 mg/10 mcg/mL Injectable, 2.5 mL Vial. The product is prescription-only and was compounded by the pharmacy. The recall is being conducted due to a lack of processing controls.
The affected product includes Lot # 5333N with an expiration date of 7/12/2019, and Lot # 7000N with an expiration date of 10/18/2019. The distribution pattern for these vials includes Colorado, Texas, and Wyoming.
The U.S. Food and Drug Administration has classified this recall as Class II. Consumers and healthcare providers who have these specific vials should stop using them and contact their pharmacist or physician for further instructions.
The recalled product
- Product
- Papaverine/Phentolamine/Alprostadil - 30 mg/1 mg/10 mcg/mL Injectable, 2.5 mL Vial, Rx only, Compounded by Wise Pharmacy, Littleton, CO 80123.
- Manufacturer
- Wise Pharmacy
- Category
- Drug — Compounded Injectable
- Affected units
- 44
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 5333N
- Exp 7/12/2019
- 7000N
- Exp 10/18/2019
Distribution
Part of a larger recall action
This product is one of 11 recalled by Wise Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Wise Pharmacy
See all →- ModerateWise Pharmacy Recalls Dexamethasone Sodium Phosphate Injection Due to Processing Controls
FDA (Drugs) · 2019-08-07
- SevereWise Pharmacy Recalls Compounded Papaverine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
- SevereWise Pharmacy Recalls Acetylcysteine Otic Drops Due to Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Gentamicin Irrigation Solution Due to Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Papaverine/Phentolamine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
Same hazard · lack of processing controls
See all →- ModerateMasterPharm Recalls Vardenafil Troches Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Troches Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Yohimbine HCL Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Calcium Citrate Powder Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
Similar recalls
- SevereFDA Recalls Papaverine, Phentolamine, and Alprostadil Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
- High
- HighFDA Recalls Compounded Papaverine-Phentolamine-PGE1 Injectable Due to Insanitary Conditions
FDA (Drugs) · 2019-04-17
- SevereFDA Recalls Papaverine-Phentolamine Injectable Due to Insanitary Compounding Conditions
FDA (Drugs) · 2019-04-17
- SevereFDA Recalls Compounded Injectable Drug Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- HighFDA Recalls Papaverine/Phentolamine Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2023-02-01